Successful and On-going Long-Term Disease Control (>24 Months) with Gilteritinib in an ALK+ NSCLC Patient with Brain Metastasis Who Has Progressed on Multiple ALK TKIs. A Case Report and Review of Literature on Gilteritnib

Sai-Hong Ignatius Ou,1,2 Cathleen June Park,1,2 Zhaohui Liao Arter,1,2 Misako Nagasaka1,2 1Department of Medicine, University of California Irvine School of Medicine, Orange, CA, 92868, USA; 2Chao Family Comprehensive Cancer Center, Orange, CA, 92868, USACorrespondence: Sai-Hong Ignatius Ou, Univers...

Full description

Bibliographic Details

Published in:	Lung Cancer: Targets and Therapy
Main Authors:	Ou SHI, Park CJ, Arter ZL, Nagasaka M
Format:	Article
Language:	English
Published:	Dove Medical Press 2025-10-01
Subjects:	Gilteritinib Lorlatinib ALK fusion non-small cell lung cancer
Online Access:	https://www.dovepress.com/successful-and-on-going-long-term-disease-control-24-months-with-gilte-peer-reviewed-fulltext-article-LCTT